Legend (LEGN)
Healthcare
Close on Nov 10, 2026 (from our latest article): $20.41
- Market value
- $4.0Bat the Nov 10 close
- FCF margin
- −14%12 months to Sep 30, 2026 (6-K)
- Net cash
- $808Mat Sep 30, 2026
- Worst fall since listing
- −79.1%Jul 28, 2023 to Nov 16, 2026; not back to that high (−79.0% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for Legend, FY2024–FY2025, from its 20-F annual reports; the latest periods from its 6-K filings.
Revenue and free cash flow
Revenue went from $627M in FY2024 to $1.0B in FY2025.
Free cash flow was positive in 0 of the 2 years shown; FY2025: −$129M.
Margins
Margins are not charted: fewer than two years with revenue and operating income.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.0B | — | — | −$297M | −$100M | $29M | −$129M |
| FY2024 | $627M | — | — | −$177M | −$144M | $14M | −$158M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | — | $949M | $319M | — | — | — |
| FY2024 | — | $1.1B | $301M | — | — | — |
Source: company 20-F annual reports and 6-K filings via SEC EDGAR (our reviewed figures); fiscal years. Data fetched Nov 10, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 20-F and 6-K data.
- Legend reports under IFRS in US dollars. SEC companyfacts holds its figures only through Dec 31, 2025, so the 2026 interim figures come from its 6-K reports.
- Debt is the collaboration interest-bearing advanced funding from Janssen (J&J) shown on the statement of financial position (Note 10 calls the advances interest-bearing borrowings). IFRS 16 lease liabilities are excluded; including them, debt would be $350.6M (2024), $413.7M (2025) and $167.4M (Sep 30, 2026).
- Short-term investments are current time deposits (original maturities over three months, not cash equivalents); non-current deposits are excluded.
- Capex is purchase of property, plant and equipment only; payments to Janssen for collaboration assets ($55.1M in the 12 months to Sep 30, 2026) are not included, so free cash flow (−$187.1M over the same 12 months) excludes them.
- FY2025 net loss includes a $169.1M unrealized foreign exchange loss. Q3 2026 includes a share-based compensation credit from forfeited awards: the release reconciliation shows a $9.6M net credit; the finance chief described a $24M one-time credit on the call.
- A foreign filer whose latest figures aren't in SEC's XBRL data yet: the annual figures are from its 20-F annual reports and the trailing 12 months combine the last full year with its 6-K filings (reviewed). They switch to SEC data once its XBRL data covers them.
Returns by year
| Year | LEGN | S&P 500 |
|---|---|---|
| 2019 | — | +31.5% |
| 2020 | −23.9%† | +18.4% |
| 2021 | +65.5% | +28.7% |
| 2022 | +7.1% | −18.1% |
| 2023 | +20.5% | +26.3% |
| 2024 | −45.9% | +25.0% |
| 2025 | −33.2% | +17.9% |
| 2026 to date | −25.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Jun 5, 2020); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- IRTC iRhythm Down 30.7%
- IBRX ImmunityBio Down 17.7%
- VCYT Veracyte Down 54.3%
- PACB PacBio Down 11.4%
- IDXX IDEXX Laboratories Up 21.8%
Questions about Legend
- Why did Legend stock fall on Nov 10, 2026?
- Legend Biotech fell 16% after finance chief Carlos Santos said analysts' forecasts for its multiple myeloma therapy Carvykti, sold with Johnson & Johnson, sit at the high end of the company's own scenarios for the fourth quarter and 2027, citing slower US uptake earlier in treatment and delayed launches abroad. The flat US sales behind the comment had been public since J&J's Oct 13 report, after which the shares had risen 36%. Read the article →